



#InvestEUresearch



Horizon 2020 Work Programme for Research & Innovation 2018-2020

Implementation science and scale up of interventions

Barbara Kerstiens, Karim Berkouk, Sasa Jenko
Health Directorate
DG Research and Innovation
European Commission

Research and
Innovation



**'Knowledge without practice is useless.
Practice without knowledge is dangerous'.**

Confucius

For a policy maker...

**What good is
knowledge
without action?**

**research is not
complete until it
is used ...**

The science-practice gap

idea



knowledge
creation



demonstration

up-take

in health
systems

in policies



Implementation
research

© Colebrooke Centre for Evidence and Implementation 2013



EU funded
research



In Europe
and worldwide



www.shutterstock.com - 523349092



Implementation research specifically takes into account the **context** and **real-life conditions** and **engages concerned population groups**, leading to more successful implementation and scale-up of public health interventions.



Relevant topic

SC1-BHC-19-2019: Implementation research for maternal and child health (up to 1000 days)

€ 35 M

Scope:

- **new or improved health service delivery interventions** that strengthen maternal and child health *and/or*
- the **scaling up and/or adapting of existing** evidence-based interventions to **new contexts**

No pre-clinical research nor clinical trials in the context of product development

In HIC or LMIC or a combination

<https://ec.europa.eu/programmes/horizon2020/node/1602>

SC1-BHC-19-2019: Implementation research for maternal and child health (up to 1000 days)

Expected impact:

- Research-supported **solutions** to maternal and child health challenges.
- evidence of successful and/or innovative **approaches for bridging the "knowledge-do" gap**
- Better understanding of **scaling-up processes**
- Contribution to the achievement of **SDGs** (2, 3, 5 & 10)

<https://ec.europa.eu/programmes/horizon2020/node/1602>

SC1-BHC-16-2018: Scaling-up of evidence-based health interventions at population level for the prevention and management of hypertension and/or diabetes

€ 20 M

<https://ec.europa.eu/programmes/horizon2020/node/1602>
<http://www.gacd.org/>

- Focus on low and middle income countries or in vulnerable populations in high income countries
- Generate expertise in implementation research & scaling up interventions in NCDs



14 GACD Members



Argentina's
Ministry of Science,
Technology
and Productive
Innovation
(MINCYT)



Australia's
National Health
and Medical
Research Council
(NHMRC)



Brazil's São
Paulo Research
Foundation
(FAPESP)



Canadian
Institutes
of Health
Research
(CIHR)



Chinese
Academy
of Medical
Sciences
(CAMS)



European
Commission's
Health Directorate
of the Research
& Innovation
Directorate General



Indian Council
of Medical
Research
(ICMR)



Japan Agency
for Medical
Research and
Development
(AMED)



Mexico's
National
Institute of
Medical
Science &
Nutrition
Salvador
Zubirán



South African
Medical
Research
Council
(SA MRC)



Thailand's
Health Systems
Research
Institute (HSRI)



UK's Medical
Research
Council
(UK MRC)




US National
Institutes of
Health (NIH)




European
Commission

A global community of researchers in NCDs

- Who work towards understanding how socio-economic, cultural, geopolitical and policy contexts have influenced results
- Cumulative learning across the individual projects
- Findings to be scaled-up and applied in different settings



GACD funding on Implementation Research (€ 200 Million so far)



Topic

Scaling-up of evidence-based health interventions at population level for the prevention and management of hypertension and/or diabetes

General Scope

- **Proposals addressing comorbidities with either hypertension or diabetes, including between them, are encouraged.**
- **Implementation research**
- **Low or middle Income Countries or vulnerable populations in High Income countries**

Scope

- Proposals **must align with commitments or planned commitments at a regional or country level** to implement evidence-based interventions.
- **Policymakers, intervention payers** (excluding research funding agencies), **researchers** (including local researchers), **implementers and beneficiaries** should **be involved at all stages of the intervention development and implementation design** to identify the challenges to intervention delivery in real settings.
- **Such partners will be integral to the success and sustainability of the programme** and it is essential that they are engaged early, and participate actively in the design of the research proposal. Researchers should collaborate closely with the authorities responsible for the programme's delivery.
- Those authorities **must pay for and provide the interventions**, possibly through **loans contracted from development banks or other financial providers**.

Scope

- **Identify, develop, test, evaluate and/or refine strategies** to scale-up evidence-based practices into public health, clinical practice, and community settings.
- Identify, understand, and develop strategies **for overcoming barriers to the adoption, adaptation, integration, scale-up** and sustainability of evidence-based interventions, tools, policies, and guidelines.
- They should address **a range of scale-up challenges**, including complex processes, inefficient use of resources, inequitable allocation of resources, and supply and demand barriers to scaling-up and sustainability.
- Use **scale-up methods, tools, and approaches to enhancing** equity, efficiency, people-centred, and responsive health systems, promoting a culture of evidence-informed learning, engaging stakeholders, and improving decisions on policies and programmes to achieve better health outcomes.
- Identify, understand, and develop strategies **for measuring the unintended consequences of intervening** at a system level.

Scope

The proposal **will cover the research around the scaling up of the interventions**. The research may cover:

- **Identification** of the best evidence-based interventions;
- Definition and implementation of **optimum scale-up methods** (e.g. pilots in multiple settings, defining a scalable unit);
- **Embed real time monitoring/evaluation** to refine protocols and ensure adaptability and effective uptake;
- **Evaluation of health outcomes**;
- Where appropriate, **make recommendations for the replication of the applied scale-up interventions** to other countries or very large regions.
- Include **health economic assessments** as an integral part of the proposed research

Expected Impacts (one of or combinations of)

- Enhanced **programmes and policies that can significantly reduce the numbers of patients with hypertension and/or diabetes** through prevention.
- Enhanced programmes and policies that can significantly **increase the number of patients** for whom hypertension and/or diabetes **was previously undetected**.
- Enhanced programmes and policies that can significantly **increase the number of patients** for whom hypertension and/or diabetes **is controlled**.
- Enhanced **effective, efficient, equitable and sustainable health systems**, to **lesser inequalities and greater health equity and additional societal benefits**, in the medium and long-term.
- Improved health services **more responsive to the need of the comorbidities** of hypertension and diabetes and other non-communicable diseases.
- **Recommendations to translate findings to other countries** or very large regions.
- Contribute to the attainment of **the SGGs for NCDs**

Thank you!

@EUScienceInnov

#InvestEUresearch

#EUHealthResearch

<http://ec.europa.eu/research/health>

<http://ec.europa.eu/research/participants/portal>